Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2021-08-27 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
关于上海泽润生物科技有限公司设立全资子公司并投资建设重组新型冠状病毒疫苗（CHO细胞）产业化项目的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company about the establishment of a wholly-owned subsidiary and investment in a new vaccine industrialization project. It details the project background, investment amount, company information, and risk factors. There are no financial statements or detailed financial performance data presented. The document is a corporate announcement about capital investment and subsidiary formation, which fits the category of Capital/Financing Update (CAP). The document length is about 3,196 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is CAP with high confidence.
2021-08-27 Chinese
独立董事关于续聘公司2021年度审计机构的事前认可意见
Audit Report / Information Classification · 95% confidence The document is a statement from independent directors providing prior approval for the reappointment of the company's 2021 audit firm. It references regulatory guidelines and the audit firm qualifications but does not contain actual audit results or financial statements. The document is short (521 characters) and serves as an opinion or approval related to the audit firm appointment rather than the audit report itself. Therefore, it fits best under Audit Report / Information (AR), which includes standalone audit-related information excluding full annual reports. FY 2021
2021-08-27 Chinese
2021年半年度报告披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (418 characters) from a company about the disclosure of its 2021 semi-annual report. It states that the 2021 half-year report and its summary were approved by the board and published on a regulatory website. The document does not contain the actual financial data or the report itself but informs investors where to find the report. According to the 'Menu vs Meal' rule, such a brief notice about the report's publication is classified as a Report Publication Announcement (RPA), not the report itself (IR).
2021-08-27 Chinese
关于拟续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an audit firm (DaXin CPA Firm) for the 2021 fiscal year. It details the qualifications, experience, and independence of the audit firm and the audit committee's approval process. It does not contain any actual audit report or financial statements but rather discusses the intention to continue the audit engagement and the procedural approvals required. The document length is 4076 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR) because it relates specifically to audit matters and the appointment of the auditor, but it is not the full audit report itself. It is not a Regulatory Filing (RNS) because it is more specific to audit information, nor is it a Report Publication Announcement (RPA) since it does not announce the publication of a report but the reappointment of the auditor. FY 2021
2021-08-27 Chinese
2021年上半年募集资金存放与实际使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "专项报告" (special report) on the storage and actual use of raised funds for the first half of 2021 by Yunnan Watson Biotechnology Co., Ltd. It details the amounts raised in initial public offerings and subsequent share issuance, the cumulative use of these funds over multiple years, the management and storage of these funds in dedicated accounts, and the temporary use of idle funds to supplement working capital. The document includes detailed financial figures related to fundraising and fund usage but does not present a full annual or interim financial report with comprehensive financial statements or management discussion and analysis. It is a specialized report focused on the use and management of raised capital, which aligns with a Capital/Financing Update (CAP) filing type. The document is lengthy (15,000 characters) and contains substantive financial data related to fundraising and capital use, not merely an announcement or certification. Therefore, the best classification is CAP with high confidence.
2021-08-27 Chinese
2021年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '云南沃森生物技术股份有限公司 2021 年半年度报告全文' which translates to 'Yunnan Walvax Biotechnology Co., Ltd. 2021 Semi-Annual Report Full Text'. It contains detailed financial data, management discussion and analysis, company overview, business outlook, and other comprehensive information typical of a semi-annual or interim financial report. The report period is specified as January 1, 2021 to June 30, 2021, confirming it covers a half-year period. The document is lengthy (15,000 characters) and includes substantive financial statements and analysis, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.